|
Synonyms: AD-85481 | ALN-85481 | ALN-AGT01
Compound class:
Nucleic acid
Comment: Zilebesiran (ALN-AGT01) is a small interfering RNA (siRNA) that is designed to target angiotensinogen (AGT) mRNA in the liver as a mechanism to treat hypertension [1-2]. The molecule is N-acetylgalactosamine (GalNAc) modified to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs). In the nucleotide sequences provided here (from the INN record) the GalNAc sugar is attached at the R1 position. The nucleotides are chemically modified (2'-O-methylnucleotides/2'-MOE and 2'-deoxy-2'-fluoronucleotide/2'-F monomers), with a mixed phosphorothioate/phosphate backbone.
|
| No information available. |
Summary of Clinical Use ![]() |
| Zilebesiran (ALN-AGT01) was progressed as a clinical candidate. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04936035 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension | Phase 2 Interventional | Alnylam Pharmaceuticals | ||
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | Phase 3 Interventional | Alnylam Pharmaceuticals | ||
| NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran | Phase 2 Interventional | Alnylam Pharmaceuticals | ||